For people who develop Parkinson's disease before age 50, the cause has often been a mystery. A new global analysis of genetic data now points to specific spots in our DNA that may trigger the illness early in life. Researchers looked at over 1,500 patients with Parkinson's and more than 20,000 healthy people to find these links. They focused on common and rare genetic changes that might increase risk. The study involved experts from the Global Parkinson's Genetic Program and other major international groups. They found six new locations in the genome that are strongly connected to early-onset cases. They also found nine more locations when looking at how genes work together. People who got sick between ages 18 and 40 had higher genetic risk scores than those who developed the disease later. This helps explain why some people get the disease so young while others do not. The findings suggest that having two copies of a specific gene change might drive this risk. However, scientists say these results need to be checked by other teams before they are used in clinics. This research is a step toward precision medicine, which tailors care to a person's unique biology. Understanding these genetic roots could one day help doctors predict who is at risk and find new ways to stop the disease before it starts.
Six novel loci and nine recessive loci identified for young onset Parkinson's disease in European ancestryGenetic clues to young onset Parkinson's disease found in large global study
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This is a meta-analysis of genome-wide association studies from the Global Parkinson's Genetic Program, the International Parkinson's Disease Genomics Consortium, and the NeuroGenetics Research Consortium. The scope was to identify genetic loci associated with young onset Parkinson's disease in European ancestry populations.
The authors synthesized results from 1,528 Parkinson's disease patients and 20,408 controls. Additive model meta-analysis identified six independent loci passing a genome-wide significance threshold, with two novel loci showing P = 1.24e-8 and P = 4.89e-8. Recessive model meta-analysis identified nine loci passing a genome-wide significance threshold. Polygenic risk scores were significantly higher in patients with onset between 18 and 40 years than in later onset patients.
The authors note that association signals suggest genetic susceptibility may be partially driven by homozygous variation. Key limitations include the need for independent replication, as stated by the authors. Practice relevance is noted as implications for future precision medicine, but clinical application is premature without replication.